Brought to you by 
Aventis to co-develop, -promote Regeneron's VEGF Trap
22 May 2015
Executive Summary
Aventis agreed to pay Regeneron up to €460mm ($510mm) for worldwide exclusive joint development and marketing rights (excluding Japan) to Regeneron's lead anti-angiogenesis compound VEGF Trap (vascular endothelial growth factor), which is in Phase I clinical trials for solid-tumors and non-Hodgkin's lymphoma.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com